Jun 17, 2021 / 02:30PM GMT
Roy Buchanan - JMP Group LLC - Analyst
All right. Well, thanks, everyone, for joining us again for the JMP Securities life sciences conference. My name is Roy Buchanan. I'm on the biotech team, on the research side. And the next company we have is Enanta Pharmaceuticals. We cover it with a market outperform rating. And we have Jay Luly, the President and CEO of Enanta. Enanta is almost solely focused on small molecule treatments for important viral pathogens, and they've successfully developed one of the components of AbbVie's approved hepatitis C drug, MAVYRET.
So I'm not sure, Jay, if you wanted to give a quick intro to Enanta, or we can just dive into the questions?
Jay Luly - Enanta Pharmaceuticals, Inc. - President, CEO and Director
Yes, maybe just a very, very brief intro. And before I begin, I want to remind people I will be making some forward-looking statements today. And for a summary of the risks associated with these statements, please see our filings on SEC.gov and on our website.
Yes, so for those less familiar, Enanta is a drug
Enanta Pharmaceuticals Inc at JMP Securities Life Sciences Virtual Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers